Phase 1 Prostate Cancer Trial, Recruiting NCT07271017 Sponsor: Johns Hopkins University Condition: Prostate Cancer
Back to Prostate Cancer

Phase 1 Prostate Cancer Trial, Recruiting

NCT07271017
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Men between the ages of 40 and 75
  • Men who have at least one of the following risk factors: a PSA blood test result above 4.0 ng/ml, an abnormal prostate exam performed by a doctor using their finger (called a digital rectal exam), or a previous biopsy that found unusual but not clearly cancerous cells (a finding called ASAP)
  • Men who have already had a specific type of prostate scan (called mpMRI or bpMRI), regardless of what the scan results showed

Who may not be able to join:

  • People for whom a prostate scan result is not available
  • Women and children, as this trial focuses specifically on prostate cancer
  • People for whom a prostate biopsy is considered too risky — this includes those who have had previous rectal surgery, have a narrowing of the anal canal, have a blood-clotting disorder, or are currently taking blood-thinning medications such as Coumadin, Lovenox, or Heparin
  • People for whom the local numbing injection used during the biopsy procedure is considered unsafe or not suitable
  • People who have already had a prostate biopsy performed using the specific investigational device being studied in this trial (called the ProBot device)
  • People from vulnerable groups, such as prisoners or those living in institutions
  • People who are unwilling or unable to sign a consent form agreeing to take part in the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Misop Han, MD, Johns Hopkins University

Phone: 410-502-5500

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
23 September 2025
Est. completion
31 May 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Device feasibility as assessed by patient discomfort score; Device feasibility as assessed by maximal procedural pain; Device feasibility as assessed by the rate of complications; Device feasibility as assessed by serious adverse events; Device feasibility as assessed by the rate of successful completion of cases; Device feasibility as assessed by the procedure time

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov